Combination Therapy for Cancer of the Head and Neck

What we are studying

The standard treatment for your cancer is radiation given at the same time as a chemotherapy drug called Cisplatin. The purpose of this research protocol is to study if the combination of the three chemotherapeutic drugs: Taxotere, Cisplatin and 5-Fluorouracil, given before the radiotherapy combined with a drug that enhances radiation effect, Erbitux, will improve chances to get rid of the cancer and prevent it from growing back.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Confirmed diagnosis of squamous cell carcinoma of the head and neck
  • Stage III or IV
  • No prior radiotherapy or chemotherapy for the study cancer
  • No chemotherapy; biologic therapy or hormonotherapy within the last one year

What is involved

  • 3 courses of chemotherapy 3 weeks apart
  • 1 month later patients will start Erbitux administered weekly through the duration of radiotherapy
  • Radiotherapy will be 5 days a week for 6 weeks
  • Follow-Up visits 4 weeks and 8 weeks post-treatment; then every 2 months for up to 2 years; every 3 months for year 3; every 6 months for up to 5 years; and yearly thereafter

Compensation

None

Contact Information

Study Coordinator
Thomas Freeman
Email
thfreema@wakehealth.edu
Phone
Not Listed

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.